INDV Stock Forecast & Price Target

Indivior Pharmaceuticals has demonstrated robust growth in its key product, Sublocade, with a significant increase in the number of patients treated, rising to approximately 171,500 in the third quarter of 2025, which signifies an 8% year-over-year growth. Additionally, the expansion in prescribers, increasing by 11% to around 8,568, reflects an improving acceptance and outreach for Sublocade, further supporting sales expectations of $825 million to $845 million for the year. The anticipated long-term growth trajectory, alongside effective cost control measures, positions Indivior favorably for continued sales expansion and potential multiple expansion in the coming years.

Indivior Pharmaceuticals faces a negative outlook primarily due to a significant contraction in its operational footprint for Sublocade, which has been reduced to commercial support in only four countries from approximately forty. Additionally, the discontinuation of commercial support for Opvee highlights a lack of synergy with the company's core products, further consolidating its market presence. The anticipated ~6.5% revenue decline in 2026, as a result of the portfolio simplification actions expected in 2025, indicates ongoing challenges in revenue generation despite potential for improved EBITDA margins from Sublocade's growth.